| Recruiting | 3 | 150 | Europe, US, RoW | Red Blood Cell, Red blood cell (RBC), Standard of care | Gladwin, Mark, MD, National Heart, Lung, and Blood Institute (NHLBI) | Sickle Cell Disease | 12/25 | 04/26 | | |
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD |
|
|
| Recruiting | N/A | 1000 | US | Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta® | Pfizer, Pfizer | Sickle Cell Disease | 01/30 | 01/30 | | |
| Recruiting | N/A | 3000 | US | | American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S | Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease | 06/35 | 12/35 | | |
